Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease.

TitleImpact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2018
AuthorsBelitskaya-Lévy I, Dysken M, Guarino P, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg G
JournalAlzheimers Dement (N Y)
Volume4
Pagination344-349
Date Published2018
ISSN2352-8737
Abstract

Introduction: Because apolipoprotein E (APOE) genotypes are known risk factors for Alzheimer's disease (AD), they have been measured in clinical trial participants to determine their effect on treatment outcome.

Methods: We determined APOE genotypes in a subset of subjects (N = 415) who participated in a randomized controlled trial of vitamin E and memantine in 613 veterans with mild-to-moderate AD.

Results: Similar to the primary study, substudy participants receiving vitamin E also had slower functional decline than those receiving placebo. Overall, there was no difference in the rate of functional decline between APOE ε4 allele carriers and noncarriers. A significant interaction was observed between treatment and the APOE genotype on AD progression: ε4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm.

Discussion: APOE genotypes may modulate AD treatment response and should be included in the design of future randomized controlled trials.
DOI10.1016/j.trci.2018.06.001
Alternate JournalAlzheimers Dement (N Y)
PubMed ID30175228
PubMed Central IDPMC6118101
Grant ListP50 AG033514 / AG / NIA NIH HHS / United States